NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis $10.02 -0.48 (-4.57%) As of 08/8/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Daxor Stock (NASDAQ:DXR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Daxor alerts:Sign Up Key Stats Today's Range$9.80▼$10.4050-Day Range$8.38▼$10.5052-Week Range$6.55▼$11.21Volume34,762 shsAverage Volume73,073 shsMarket Capitalization$48.50 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingBuy Company Overview Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh. Read More Daxor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreDXR MarketRank™: Daxor scored higher than 79% of companies evaluated by MarketBeat, and ranked 200th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDaxor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDaxor has received no research coverage in the past 90 days.Read more about Daxor's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.53% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daxor has recently decreased by 12.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaxor does not currently pay a dividend.Dividend GrowthDaxor does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.53% of the float of Daxor has been sold short.Short Interest Ratio / Days to CoverDaxor has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daxor has recently decreased by 12.10%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.19 News SentimentDaxor has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Daxor this week, compared to 1 article on an average week.Search Interest1 people have searched for DXR on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Daxor insiders have not sold or bought any company stock.Percentage Held by Insiders59.50% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.34% of the stock of Daxor is held by institutions.Read more about Daxor's insider trading history. Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Email Address DXR Stock News HeadlinesDaxor Gains FDA Clearance for Blood Volume AnalyzerAugust 7 at 8:59 AM | tipranks.comDaxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis SystemAugust 7 at 8:35 AM | gurufocus.comWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast. | InvestorPlace (Ad)Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis ...August 7 at 8:34 AM | gurufocus.comDaxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis SystemAugust 7 at 7:55 AM | globenewswire.comDaxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility AdoptionsJuly 22, 2025 | globenewswire.comDaxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart JournalMay 14, 2025 | globenewswire.comDaxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare SystemsMay 13, 2025 | globenewswire.comSee More Headlines DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed this year? Daxor's stock was trading at $7.69 on January 1st, 2025. Since then, DXR stock has increased by 30.3% and is now trading at $10.02. How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS) and Company Calendar Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryMedical Equipment Current SymbolNASDAQ:DXR CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806Employees37Year FoundedN/APrice Target and Rating Average Price Target for Daxor$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+149.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,840,000Free Float1,959,000Market Cap$48.50 million OptionableNot Optionable Beta-0.13 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DXR) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.